Issue Type: Payer and Supply Chain Economics Favor Higher Cost Drugs

in challenge narrative

  • The Big Problem With High Health Care Deductibles

  • Here Are the 5 Drug Classes with the Biggest Price Gains

  • Why Drugs Cost So Much

  • Understanding the Rewards of Successful Drug Development: Thinking Inside the Box

  • Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

    Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

  • Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries

  • Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

    Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

  • DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)

  • Spending On Prescription Drugs In The US: Where Does All The Money Go?

    Spending On Prescription Drugs In The US: Where Does All The Money Go?

  • DPL responds to HHS Blueprint (May 16, 2018)